-. Accenture, High performance drug discovery: an operating model for a new era, 2001.

J. Aubert, P. Reiniche, P. Fogel, Y. Poulin, H. Lui et al., Gene expression profiling in psoriatic scalp hair follicles :clobetasol propionate shampoo 0.05% normalizes psoriasis disease markers.European Academy of Dermatology and Venerology, 2010.

O. Baadsgaard, Optimal concentration of tacalcitol in once-daily treatment of psoriasis, Journal of Dermatological Treatment, vol.51, issue.3, pp.145-150, 1990.
DOI : 10.2337/diab.41.11.1491

C. L. Barker, M. T. Mchale, A. K. Gillies, J. Waller, D. M. Pearce et al., The Development and Characterization of an In Vitro Model of Psoriasis, Journal of Investigative Dermatology, vol.123, issue.5, pp.892-901, 2004.
DOI : 10.1111/j.0022-202X.2004.23435.x

T. Bateman, Practical synopsis of cutaneous disease, according to the arrangement of Dr, 1836.

J. A. Dimasi and H. G. Grabowski, The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial and Decision Economics, pp.4-5469, 2007.

J. A. Dimasi, The price of innovation: new estimates of drug development costs, Journal of Health Economics, vol.22, issue.2, pp.151-185, 2003.
DOI : 10.1016/S0167-6296(02)00126-1

J. A. Dimasi, L. Feldman, A. Seckler, and A. Wilson, Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs, Clinical Pharmacology & Therapeutics, vol.36, issue.3, pp.272-279, 2010.
DOI : 10.2174/138920108786786358

J. Dingemanse and S. Appel-­?dingemanse, Integrated??Pharmacokinetics??and Pharmacodynamics in??Drug??Development, Clinical Pharmacokinetics, vol.57, issue.2, pp.713-737, 2007.
DOI : 10.2165/00003088-200746090-00001

K. J. Dumas and J. R. Scholtz, The psoriasis bio-­?assay for topical corticosteroid activity. Acta Dermato-­?Venereologica, pp.43-48, 1972.

M. H. Fadzil, H. Fitriyah, E. Prakasa, H. Nugroho, S. H. Hussein et al., Objective Assessment of psoriasis lesion thickness for PASI Scoring using 3D Digital imaging, World Academy of science, Engineering and Technology, vol.63, 2010.

A. Y. Finlay and J. P. Ortonne, Patient Satisfaction with Psoriasis Therapies: An Update and Introduction to Biologic Therapy, Journal of Cutaneous Medicine and Surgery, vol.2, issue.Suppl 67, pp.310-330, 2004.
DOI : 10.1007/s10227-005-0030-6

M. Forster, M. A. Bolzinger, H. Fessi, and S. Briançon, Topical delivery of cosmetics and drugs. Molecular aspects of percutaneous absorption and delivery, European Journal of Dermatology, vol.19, issue.4, pp.309-332, 2009.

T. J. Franz, The Finite Dose Technique as a Valid in vitro Model for the Study of Percutaneous Absorption in Man, Current Problems in Dermatology, vol.7, pp.58-68, 1979.
DOI : 10.1159/000401276

P. Y. Muller and F. Dieterle, Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring, Expert Opinion on Drug Metabolism & Toxicology, vol.39, issue.9, pp.1023-1038, 2009.
DOI : 10.2215/CJN.04010907

L. Naldi, F. O. Nestle, D. H. Kaplan, and J. Barker, Epidemiology of Psoriasis, Current Drug Target -Inflammation & Allergy, vol.3, issue.2, pp.121-128496, 2004.
DOI : 10.2174/1568010043343958

O. Ocde, OECD Guideline for the testing of chemicals: Skin Absorption: in-­?vitro Method, p.428, 2004.

T. K. Petersen and P. Sørensen, Translational dermatology in drug discovery: perspectives for integrating humanized xenograft models and experimental clinical studies, Drug Discovery Today, vol.13, issue.5-6, 2008.
DOI : 10.1016/j.drudis.2007.10.009

R. L. Phillips and A. B. Sachs, Skin biopsies for the measurmement of clinical pharmacodynamic biomarkers. Current opinion in biotechnology, pp.687-690, 2005.

I. Poggesi, Predicting human pharmacokinetics from preclinical data. Current opinion in drug discovery & Development, pp.100-111, 2004.

R. C. Trembath, R. L. Clough, and J. L. Rosbotham, Identification of a Major Susceptibility Locus on Chromosome 6p and Evidence for Further Disease Loci Revealed by a Two Stage Genome-Wide Search in Psoriasis, Human Molecular Genetics, vol.6, issue.5, pp.813-820, 1997.
DOI : 10.1093/hmg/6.5.813

J. A. Vernon, J. H. Golec, and J. A. Dimasi, Drug development costs when financial risk is measured using the Fama-French three-factor model, Health Economics, vol.37, issue.Suppl. 3, 2009.
DOI : 10.1002/hec.1538

M. Wehling, Translational Science in Medicine, International Journal of Pharmaceutical Medicine, vol.52, issue.5, pp.303-313, 2006.
DOI : 10.2165/00124363-200620050-00004

J. Woodcock and R. Woosley, The FDA Critical Path Initiative and Its Influence on New Drug Development, Annual Review of Medicine, vol.59, issue.1, pp.1-12, 2008.
DOI : 10.1146/annurev.med.59.090506.155819